Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Drug Repurposing in Cancer Research: A Bibliometric Analysis from 2012 to 2021

Author(s): Elif Burcu Bali*

Volume 19, Issue 2, 2023

Published on: 26 December, 2022

Page: [156 - 170] Pages: 15

DOI: 10.2174/1573394718666220928152207

Price: $65

Abstract

Background: In this study, it was aimed to evaluate the research articles indexed on the Web of Science about drug repurposing in cancer between 2012 and November 2021.

Methods: Findings were obtained from the Web of Science database. A bibliometric method was performed to analyze publication types, research fields, citations, countries, institutions, active journals, authors, and keywords. The data were supported by using collaboration networks, including visualization maps. Globally, of 5,568 publications, only 408 were research papers in cancer research. However, the number of publications and citations was observed to increase significantly over the years, especially in 2020 and 2021. The majority of the publication types were original articles in the oncology field. Unsurprisingly, the USA was the most active country in publishing articles.

Results: The University of Texas in the USA was the institution with the highest number of publications. A team of researchers led by Zdenek Skrott published the most cited paper. While Pantziarka’s research team was the most active in publication productivity, Ferlay J’s research group had the highest value of citation burst. Cancers and Cancer Research were the most active journals in terms of publications and citation numbers, respectively. After the keyword drug repurposing, the most frequently used keywords were “apoptosis” and “breast cancer”, indicating the research hotspots.

Conclusion: This is the first bibliometric research in detail to point out that drug repurposing in cancer is a novel and growing area, especially in developed countries.

Keywords: cancer, apoptosis, bibliometric analysis, breast cancer, web of science, drug repurposing

« Previous Next »
Graphical Abstract

[1]
Kirtonia A, Gala K, Fernandes SG, et al. Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. Semin Cancer Biol 2021; 68: 258-78.
[http://dx.doi.org/10.1016/j.semcancer.2020.04.006] [PMID: 32380233]
[2]
Tang C, Liu D, Fan Y, et al. Visualization and bibliometric analysis of cAMP signaling system research trends and hotspots in cancer. J Cancer 2021; 12(2): 358-70.
[http://dx.doi.org/10.7150/jca.47158] [PMID: 33391432]
[3]
World Health Organization. WHO | Cancer Factsheet Who. 2021.Available from:. www.who.int/cancer/en/
[4]
Huang J, Zhao D, Liu Z, Liu F. Repurposing psychiatric drugs as anti-cancer agents. Cancer Lett 2018; 419: 257-65.
[http://dx.doi.org/10.1016/j.canlet.2018.01.058] [PMID: 29414306]
[5]
Abdelaleem M, Ezzat H, Osama M, et al. Prospects for repurposing CNS drugs for cancer treatment. Oncol Rev 2019; 13(1): 411.
[http://dx.doi.org/10.4081/oncol.2019.411] [PMID: 31044029]
[6]
Zhang Z, Zhou L, Xie N, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020; 5(1): 113.
[http://dx.doi.org/10.1038/s41392-020-00213-8] [PMID: 32616710]
[7]
Urbina F, Puhl AC, Ekins S. Recent advances in drug repurposing using machine learning. Curr Opin Chem Biol 2021; 65: 74-84.
[http://dx.doi.org/10.1016/j.cbpa.2021.06.001] [PMID: 34274565]
[8]
Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacol Res 2017; 124: 74-91.
[http://dx.doi.org/10.1016/j.phrs.2017.07.013] [PMID: 28712971]
[9]
Baker NC, Ekins S, Williams AJ, Tropsha A. A bibliometric review of drug repurposing. Drug Discov Today 2018; 23(3): 661-72.
[http://dx.doi.org/10.1016/j.drudis.2018.01.018] [PMID: 29330123]
[10]
Nowak SP, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019; 1871(2): 434-54.
[http://dx.doi.org/10.1016/j.bbcan.2019.04.005] [PMID: 31034926]
[11]
Pantziarka P, Verbaanderd C, Sukhatme V, et al. ReDO_DB: The repurposing drugs in oncology database. Ecancermedicalscience 2018; 12: 886.
[http://dx.doi.org/10.3332/ecancer.2018.886] [PMID: 30679953]
[12]
Issa NT, Stathias V, Schürer S, Dakshanamurthy S. Machine and deep learning approaches for cancer drug repurposing. Semin Cancer Biol 2021; 68: 132-42.
[http://dx.doi.org/10.1016/j.semcancer.2019.12.011] [PMID: 31904426]
[13]
Mallik A, Mandal N. Bibliometric analysis of global publication output and collaboration structure study in microRNA research. Scientometrics 2014; 98(3): 2011-37.
[http://dx.doi.org/10.1007/s11192-013-1128-z]
[14]
Aleixandre TJL, Castelló CL, Aleixandre JL, Aleixandre BR. Unravelling the scientific research on grape and wine phenolic compounds: A bibliometric study. Scientometrics 2019; 119(1): 119-47.
[http://dx.doi.org/10.1007/s11192-019-03029-8]
[15]
Kasemodel MGC, Makishi F, Souza RC, Silva VL. Following the trail of crumbs: A bibliometric study on consumer behavior in the food science and technology field. Int J Food Stud 2016; 5(1): 73-83.
[http://dx.doi.org/10.7455/ijfs/5.1.2016.a7]
[16]
Zhou X, Zhao G. Global liposome research in the period of 1995–2014: A bibliometric analysis. Scientometrics 2015; 105(1): 231-48.
[http://dx.doi.org/10.1007/s11192-015-1659-6]
[17]
Kocak M, García ZC, Marugán LS. Çakır MP, Sanz CE. Mapping and clustering analysis on neuroscience literature in Turkey: A bibliometric analysis from 2000 to 2017. Scientometrics 2019; 121(3): 1339-66.
[http://dx.doi.org/10.1007/s11192-019-03259-w]
[18]
Tan J, Fu HZ, Ho YS. A bibliometric analysis of research on proteomics in science citation index expanded. Scientometrics 2014; 98(2): 1473-90.
[http://dx.doi.org/10.1007/s11192-013-1125-2]
[19]
Mejia C, Wu M, Zhang Y, Kajikawa Y. Exploring topics in bibliometric research through citation networks and semantic analysis. Front Res Metr Anal 2021; 6: 742311.
[http://dx.doi.org/10.3389/frma.2021.742311] [PMID: 34632257]
[20]
Skrott Z, Mistrik M, Andersen KK, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017; 552(7684): 194-9.
[http://dx.doi.org/10.1038/nature25016] [PMID: 29211715]
[21]
Jahchan NS, Dudley JT, Mazur PK, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013; 3(12): 1364-77.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0183] [PMID: 24078773]
[22]
Antonarakis ES, Heath EI, Smith DC, et al. Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative ran-domized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 2013; 18(2): 163-73.
[http://dx.doi.org/10.1634/theoncologist.2012-314] [PMID: 23340005]
[23]
Chen C. The CiteSpace Manual version 077 CCI. 2014; pp. 1-84.Available from. https://www.scirp.org/%28S%28351jmbntvnsjt1aadkposzje%29%29/reference/referencespapers.aspx?referenceid=3118732
[24]
Kotepui M, Wannaiampikul S, Chupeerach C, Duangmano S. A bibliometric analysis of diets and breast cancer research. Asian Pac J Cancer Prev 2014; 15(18): 7625-8.
[http://dx.doi.org/10.7314/APJCP.2014.15.18.7625] [PMID: 25292038]
[25]
Glynn RW, Scutaru C, Kerin MJ, Sweeney KJ. Breast cancer research output, 1945-2008: A bibliometric and density-equalizing analysis. Breast Cancer Res 2010; 12(6): R108.
[http://dx.doi.org/10.1186/bcr2795] [PMID: 21176219]
[26]
Perez SJLM, Anaya RM. Mexican breast cancer research output, 2003-2012. Asian Pac J Cancer Prev 2013; 14(10): 5921-3.
[http://dx.doi.org/10.7314/APJCP.2013.14.10.5921] [PMID: 24289601]
[27]
Uysal E. Top 100 cited classic articles in breast cancer research. Eur J Breast Health 2017; 13(3): 129-37.
[http://dx.doi.org/10.5152/ejbh.2017.3480] [PMID: 28894852]
[28]
Muslu Ü. The evolution of breast reduction publications: A bibliometric analysis. Aesthetic Plast Surg 2018; 42(3): 679-91.
[http://dx.doi.org/10.1007/s00266-018-1080-7] [PMID: 29352346]
[29]
Özen Çİ. Bibliometric analysis of breast cancer research in the period 2009-2018.; Int J Nurs Pract 2020; 26(3): e12845.
[http://dx.doi.org/10.1111/ijn.12845] [PMID: 32406145]
[30]
Zhang X, Chen H, Wang W, De Pablos OP. What is the role of IT in innovation? A bibliometric analysis of research development in IT innovation. Behav Inf Technol 2016; 35(12): 1130-43.
[http://dx.doi.org/10.1080/0144929X.2016.1212403]
[31]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[32]
Cabral BP, Da Graça DFM, Mota FB. The recent landscape of cancer research worldwide: A bibliometric and network analysis. Oncotarget 2018; 9(55): 30474-84.
[http://dx.doi.org/10.18632/oncotarget.25730] [PMID: 30093962]
[33]
Datta A, Kim H, McGee L, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep 2018; 8(1): 8161.
[http://dx.doi.org/10.1038/s41598-018-26411-7] [PMID: 29802284]
[34]
Schipper LJ, Zeverijn LJ, Garnett MJ, Voest EE. Can drug repurposing accelerate precision oncology? Cancer Discov 2022; 12(7): 1634-41.
[http://dx.doi.org/10.1158/2159-8290.CD-21-0612] [PMID: 35642948]
[35]
Heckman SBM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 2017; 60(9): 1639-47.
[http://dx.doi.org/10.1007/s00125-017-4372-6] [PMID: 28776080]
[36]
Lu C, Li X, Ren Y, Zhang X. Disulfiram: A novel repurposed drug for cancer therapy. Cancer Chemother Pharmacol 2021; 87(2): 159-72.
[http://dx.doi.org/10.1007/s00280-020-04216-8] [PMID: 33426580]
[37]
Park YM, Go YY, Shin SH, Cho JG, Woo JS, Song JJ. Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death. PLoS One 2018; 13(9): e0203069.
[http://dx.doi.org/10.1371/journal.pone.0203069] [PMID: 30212479]
[38]
McMahon A, Chen W, Li F. Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy. J Control Release 2020; 319: 352-9.
[http://dx.doi.org/10.1016/j.jconrel.2020.01.001] [PMID: 31911155]
[39]
Timilsina S, Rajamanickam S, Rao A, et al. The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. Cancer Lett 2022; 540: 215717.
[http://dx.doi.org/10.1016/j.canlet.2022.215717] [PMID: 35568265]
[40]
Asensi CA, López AMD, Castillo GV, et al. Antitumoral effects of tricyclic antidepressants: Beyond neuropathic pain treatment. Cancers 2022; 14(13): 3248.
[http://dx.doi.org/10.3390/cancers14133248] [PMID: 35805019]
[41]
Pounds R, Leonard S, Dawson C, Kehoe S. Repurposing itraconazole for the treatment of cancer. Oncol Lett 2017; 14(3): 2587-97.
[http://dx.doi.org/10.3892/ol.2017.6569] [PMID: 28927025]
[42]
Hamdoun S, Jung P, Efferth T. Drug repurposing of the anthelmintic niclosamide to treat multidrug-resistant leukemia. Front Pharmacol 2017; 8: 110.
[http://dx.doi.org/10.3389/fphar.2017.00110] [PMID: 28344555]
[43]
Kaushal JB, Bhatia R, Kanchan RK, et al. Repurposing niclosamide for targeting pancreatic cancer by inhibiting Hh/Gli non-canonical axis of Gsk3β. Cancers 2021; 13(13): 3105.
[http://dx.doi.org/10.3390/cancers13133105] [PMID: 34206370]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy